vardenafil dihydrochloride

WordNet

virility drug (trade name Levitra) used to treat erectile dysfunction in men (同)Levitra

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 男性性機能不全の治療 treatment of male sexual dysfunction
2. 心血管疾患患者における性的活動 sexual activity in patients with cardiovascular disease
3. 糖尿病における勃起不全 erectile dysfunction in diabetes mellitus
4. 成人における肺高血圧症の治療 treatment of pulmonary hypertension in adults
5. 慢性血栓塞栓性肺高血圧症：内科的治療 chronic thromboembolic pulmonary hypertension medical treatment

A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes.

Mazzarino M1, Cesarei L1, de la Torre X1, Fiacco I1, Robach P2, Botrè F3.
Journal of pharmaceutical and biomedical analysis.J Pharm Biomed Anal.2016 Jan 5;117:47-60. doi: 10.1016/j.jpba.2015.08.007. Epub 2015 Aug 17.
This work presents an analytical method for the simultaneous analysis in human urine of 38 pharmacologically active compounds (19 benzodiazepine-like substances, 7 selective serotonin reuptake inhibitors, 4 azole antifungal drugs, 5 inhibitors of the phosphodiesterases type 4 and 3 inhibitors of the
PMID 26342446

Comparison of the effects of systemic sildenafil, tadalafil, and vardenafil treatments on skin flap survival in rats.

Kaya B1, Çerkez C1, Işılgan SE1, Göktürk H2, Yığman Z3, Serel S1, Can B3, Ergün H4.
Journal of plastic surgery and hand surgery.J Plast Surg Hand Surg.2015 Dec;49(6):358-62. doi: 10.3109/2000656X.2015.1041024. Epub 2015 Jun 24.
OBJECTIVE: The most important issue in flap surgery is flap viability. This study aimed to compare the effects of most commonly used phosphodiesterase type 5 (PDE5) inhibitors on flap survival.METHODS: A 3 × 9 cm flap was elevated from the dorsum of 32 Wistar albino rats. In the control group, sali
PMID 26107909

Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.

Zenzmaier C1, Kern J2, Heitz M3, Plas E4, Zwerschke W5, Mattesich M6, Sandner P7, Berger P8.
Experimental cell research.Exp Cell Res.2015 Nov 1;338(2):162-9. doi: 10.1016/j.yexcr.2015.08.014. Epub 2015 Sep 26.
BACKGROUND: Fibrotic diseases encompass numerous systemic and organ-specific disorders characterized by the development and persistence of myofibroblasts. TGFβ1 is considered the key inducer of fibrosis and drives myofibroblast differentiation in cells of diverse histological origin by a pro-oxidan
PMID 26410556